KR101060971B1 - 안트라닐산 유도체 수화물의 제조 방법 - Google Patents
안트라닐산 유도체 수화물의 제조 방법 Download PDFInfo
- Publication number
- KR101060971B1 KR101060971B1 KR1020047018344A KR20047018344A KR101060971B1 KR 101060971 B1 KR101060971 B1 KR 101060971B1 KR 1020047018344 A KR1020047018344 A KR 1020047018344A KR 20047018344 A KR20047018344 A KR 20047018344A KR 101060971 B1 KR101060971 B1 KR 101060971B1
- Authority
- KR
- South Korea
- Prior art keywords
- hydrate
- quinoline
- formula
- acid
- isoquinolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37975902P | 2002-05-14 | 2002-05-14 | |
| US60/379,759 | 2002-05-14 | ||
| PCT/GB2003/002060 WO2003095447A1 (en) | 2002-05-14 | 2003-05-13 | Process for the preparation of a hydrate of an anthranilic acid derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20050009706A KR20050009706A (ko) | 2005-01-25 |
| KR101060971B1 true KR101060971B1 (ko) | 2011-09-01 |
Family
ID=29420557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047018344A Expired - Fee Related KR101060971B1 (ko) | 2002-05-14 | 2003-05-13 | 안트라닐산 유도체 수화물의 제조 방법 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7524861B2 (https=) |
| EP (1) | EP1506188B1 (https=) |
| JP (1) | JP4464814B2 (https=) |
| KR (1) | KR101060971B1 (https=) |
| CN (1) | CN100349888C (https=) |
| AT (1) | ATE423778T1 (https=) |
| AU (1) | AU2003233899B2 (https=) |
| BR (1) | BR0309990A (https=) |
| CA (1) | CA2485430C (https=) |
| DE (1) | DE60326341D1 (https=) |
| WO (1) | WO2003095447A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100557093B1 (ko) | 2003-10-07 | 2006-03-03 | 한미약품 주식회사 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
| RS56037B1 (sr) | 2004-06-24 | 2017-09-29 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| FR2873585B1 (fr) * | 2004-07-27 | 2006-11-17 | Aventis Pharma Sa | Nouvelles formulations galeniques de principes actifs |
| EP1979367A2 (en) * | 2005-12-24 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Quinolin-4-one derivatives as modulators of abc transporters |
| EP3219705B1 (en) | 2005-12-28 | 2020-03-11 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| PL2408750T3 (pl) | 2009-03-20 | 2016-02-29 | Vertex Pharma | Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| CA2919522C (en) | 2013-07-30 | 2019-02-26 | Gilead Connecticut, Inc. | Formulation of syk inhibitors |
| EA029281B1 (ru) | 2013-07-30 | 2018-03-30 | Джилид Коннектикут, Инк. | Полиморф ингибиторов syk |
| TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
| CN103804352B (zh) * | 2014-01-23 | 2017-06-13 | 中国药科大学 | 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用 |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| CN104327046B (zh) * | 2014-10-14 | 2017-11-17 | 中国药科大学 | 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用 |
| CN104434947B (zh) * | 2014-11-07 | 2016-11-09 | 滨州医学院附属医院 | 一种抗胆管癌的药物组合物及其应用 |
| EP3378858A1 (en) * | 2017-03-21 | 2018-09-26 | Bioprojet | Tetrahydrate of h3 ligand, its process of preparation and pharmaceutical compositions comprising the same |
| CA3073871A1 (en) | 2017-08-25 | 2019-02-28 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
| CN113950479A (zh) | 2019-02-22 | 2022-01-18 | 克洛诺斯生物股份有限公司 | 作为syk抑制剂的缩合吡嗪的固体形式 |
| WO2022076662A1 (en) * | 2020-10-07 | 2022-04-14 | Athenex, Inc. | Acetamido-phenylbenzamide derivatives and methods of using the same |
| CN112724124A (zh) * | 2021-01-18 | 2021-04-30 | 林剑雄 | 4-羟基喹啉类衍生物及其制备方法和在抗肿瘤药物中的应用 |
| CN117304105A (zh) * | 2023-08-18 | 2023-12-29 | 中国科学院基础医学与肿瘤研究所(筹) | 一种靶向抑制ABCB1(P-gp)的化合物及制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK280864B6 (en) * | 1991-01-11 | 2000-08-14 | Laboratoires Glaxo Sa | Acridine derivatives, process for their preparation, and pharmaceutical compositions based thereon |
| GB9717576D0 (en) | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
| HUP0001531A3 (en) * | 1996-10-18 | 2000-09-28 | Xenova Ltd Slough | Anthranilic acid derivatives as multi drug resistance modulators |
-
2003
- 2003-05-13 US US10/513,986 patent/US7524861B2/en not_active Expired - Fee Related
- 2003-05-13 BR BR0309990-3A patent/BR0309990A/pt not_active IP Right Cessation
- 2003-05-13 AT AT03727661T patent/ATE423778T1/de not_active IP Right Cessation
- 2003-05-13 CN CNB038159295A patent/CN100349888C/zh not_active Expired - Fee Related
- 2003-05-13 KR KR1020047018344A patent/KR101060971B1/ko not_active Expired - Fee Related
- 2003-05-13 JP JP2004503463A patent/JP4464814B2/ja not_active Expired - Fee Related
- 2003-05-13 EP EP03727661A patent/EP1506188B1/en not_active Expired - Lifetime
- 2003-05-13 AU AU2003233899A patent/AU2003233899B2/en not_active Ceased
- 2003-05-13 DE DE60326341T patent/DE60326341D1/de not_active Expired - Lifetime
- 2003-05-13 WO PCT/GB2003/002060 patent/WO2003095447A1/en not_active Ceased
- 2003-05-13 CA CA2485430A patent/CA2485430C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003095447A1 (en) | 2003-11-20 |
| US20050222199A1 (en) | 2005-10-06 |
| EP1506188A1 (en) | 2005-02-16 |
| US7524861B2 (en) | 2009-04-28 |
| AU2003233899B2 (en) | 2009-03-12 |
| JP4464814B2 (ja) | 2010-05-19 |
| CN1665806A (zh) | 2005-09-07 |
| DE60326341D1 (de) | 2009-04-09 |
| EP1506188B1 (en) | 2009-02-25 |
| JP2005538051A (ja) | 2005-12-15 |
| AU2003233899A1 (en) | 2003-11-11 |
| KR20050009706A (ko) | 2005-01-25 |
| BR0309990A (pt) | 2005-02-22 |
| CA2485430A1 (en) | 2003-11-20 |
| CN100349888C (zh) | 2007-11-21 |
| ATE423778T1 (de) | 2009-03-15 |
| CA2485430C (en) | 2011-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101060971B1 (ko) | 안트라닐산 유도체 수화물의 제조 방법 | |
| CN115803325B (zh) | 一种egfr抑制剂及其制备方法和应用 | |
| CN114195788B (zh) | 一类四环化合物及其用途 | |
| CN114907387B (zh) | 嘧啶并吡咯类kras抑制剂及其制备方法与应用 | |
| CN114409653A (zh) | 一种桥环并嘧啶并环类化合物及其用途 | |
| WO2021218110A1 (zh) | 一类苯并噻唑基联芳基类化合物、制备方法和用途 | |
| KR20060027802A (ko) | ３환계 화합물 | |
| EA022341B1 (ru) | Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена | |
| CN1863795B (zh) | P-糖蛋白抑制剂,其制备方法和包括该抑制剂的药物组合物 | |
| WO2003000660A1 (fr) | Derive de quinoleine et derive de quinoleine permettant d'inhiber l'auto-phosphorylation du recepteur des proliferateurs des hepatocytes, ainsi que des compositions medicinales contenant ce derive | |
| CN115867540A (zh) | 硝羟喹啉衍生物及其制备方法和用途 | |
| CN114585621A (zh) | 咪唑并喹啉胺衍生物、及其药物组合物和应用 | |
| WO2025124460A1 (zh) | 三环稠杂环类pde3/4双重抑制剂及其制备方法与应用 | |
| RU2163599C2 (ru) | Таксаны, способ их получения и лекарственный препарат на их основе | |
| CN121013856A (zh) | Egfr降解剂、其药物组合物及其用途 | |
| CN114616234B (zh) | 磷咪唑并喹啉胺衍生物、及其药物组合物和应用 | |
| CN109081818B (zh) | 新型吲哚胺2,3-双加氧化酶抑制剂 | |
| KR20150105302A (ko) | 헤지 호그 신호 경로의 억제제로서 환상 술폰아미드 함유 유도체 | |
| CN112778154B (zh) | 芳基烷基醚化合物及其衍生物，制备方法、药物组合物和应用 | |
| TWI918767B (zh) | 含二并環類衍生物抑制劑自由鹼的晶型及其製備方法和應用 | |
| JP3153555B2 (ja) | ファルネシルタンパク質トランスフェラーゼのインヒビターとして有用な新規三環式ｎ―シアノイミン | |
| CN120192318A (zh) | 吡咯里嗪并[2,3-c]喹啉衍生物、合成方法及其应用 | |
| HK40068190A (en) | Imidazoquinoline amine derivatives, pharmaceutical compositions and use thereof | |
| CN119241548A (zh) | 含稠合苯环的二氢喋啶酮衍生物及其用途 | |
| HK40068190B (zh) | 咪唑并喹啉胺衍生物、及其药物组合物和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20140826 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20140826 |